cyproterone acetate has been researched along with Cancer of Prostate in 283 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 88 (31.10) | 18.7374 |
| 1990's | 115 (40.64) | 18.2507 |
| 2000's | 58 (20.49) | 29.6817 |
| 2010's | 19 (6.71) | 24.3611 |
| 2020's | 3 (1.06) | 2.80 |
| Authors | Studies |
|---|---|
| Asselin, E; Bastien, D; Bérubé, G; Leblanc, V | 1 |
| Blanco, F; Caboni, L; Carr, M; Fayne, D; Jagoe, WN; Kinsella, GK; Lloyd, DG; Meegan, MJ; Williams, DC | 1 |
| Asselin, É; Bastien, D; Bérubé, G; Hanna, R; Leblanc, V | 1 |
| Bérubé, G; Oufqir, Y; Paquin, A; Reyes-Moreno, C; Sevrioukova, IF | 1 |
| Chai, X; Chen, C; Cui, S; Fu, Y; He, J; Hou, T; Li, D; Pang, J; Shan, L; Sun, H; Wang, X; Xu, L; Xu, X; Yang, L; Yang, Y; Yao, X; Zhou, W | 1 |
| Ahsman, M; DeJongh, J; Snelder, N | 1 |
| Ali, J; Ben Slama, A; Hammami, A; Hanene, J; Mehdi, K; Nour, E | 1 |
| Cerný, D; Röderová, E; Sálek, T; Vodička, M | 1 |
| Antoniou, N; Calais da Silva, F; Calais da Silva, FM; Gonçalves, F; Kliment, J; Marques Queimadelos, A; Oliver, T; Pastidis, S; Robertson, C; Santos, A; Whelan, P | 1 |
| Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F | 1 |
| Bangma, CH; Bratus, D; Fiala, R; Kukk, L; Mickisch, GH; Pagi, H; Schröder, FH; Verhagen, PC; Verkerk, AM; Vjaters, E; Wildhagen, MF | 1 |
| Andrade, RJ; Bessone, F; Bruguera, M; Colombato, L; Fassio, E; Ferrer, J; Ferretti, S; Frider, B; Gualano, G; Hernández, N; Lucena, MI; Medina-Cáliz, I; Montero, J; Reggiardo, MV; Roma, MG; Stephens, C; Tanno, F; Tanno, H; Tsariktsian, G; Zeno, L | 1 |
| Buijs, JT; Culig, Z; Grimm, S; Hemmer, DM; Hwang, MS; Kroon, J; Marijt, KA; Masood, M; Meijer, OC; Metselaar, JM; Puhr, M; Storm, G; van der Horst, G; van der Pluijm, G | 1 |
| Chen, L; Lin, MF; Tu, Y; Wolff, DW; Xie, Y | 1 |
| Asim, M; Baniahmad, A; Eisold, M; Eskelinen, H; Linke, T | 1 |
| Bono, AV; Brausi, M; Calais da Silva, FE; Calais da Silva, FM; Kirkali, Z; Marques Queimadelos, A; Martin, JA; Robertson, C; Whelan, P | 1 |
| Angelucci, C; Bono, AV; Ferracuti, S; Iacopino, F; Lama, G; Millar, RP; Sica, G | 1 |
| Agoulnik, IU; Weigel, NL | 1 |
| Bouchard, P; Irani, J; Mottet, N; Oba, R; Salomon, L | 1 |
| Dubbink, HJ; Hersmus, R; Jenster, G; Lusher, SJ; Molier, M; Trapman, J; van de Wijngaart, DJ | 1 |
| Bosland, MC; Johnson, WD; Lubet, RA; McCormick, DL; Rao, KV; Steele, VE | 1 |
| Jääskeläinen, T; Kauhanen, M; Makkonen, H; Palvimo, JJ | 1 |
| Bernier, J; Billiet, I; Bolla, M; Collette, L; Cutajar, CL; Dubois, JB; Kuten, A; Mirimanoff, RO; Pfeffer, R; Sternberg, C; Storme, G; Torecilla, JL; Van der Kwast, T; Van Tienhoven, G; Warde, P | 1 |
| D'Amico, AV | 1 |
| Bagatini, MD; Battisti, IE; Battisti, V; Chiesa, J; Duarte, MM; Gonçalves, JF; Maders, LD; Morsch, VM; Reetz, LG; Schetinger, MR | 1 |
| Cho, KS; Lee, JY | 1 |
| Gardiner, RA; Green, HJ; Headley, BC; Mactaggart, PN; Nicol, DL; Pakenham, KI; Swanson, C; Watson, RB; Yaxley, J | 1 |
| Bonmassar, E; Faraoni, I; Missale, C; Rizzetti, MC; Sigala, S; Spano, P; Tognazzi, N | 1 |
| Bullock, MJ; Goldenberg, SL; Klotz, LH; Srigley, JR | 1 |
| Amir, AL; Balk, SP; Barua, M; Cheng, S; McKnight, NC; Yuan, X | 1 |
| Collette, L; de Reijke, TM; Schröder, FH | 1 |
| Barkin, J; Chatterjee, S; Chin, J; Fradet, Y; Goldenberg, SL; Jewett, MA; Klotz, LH; Nam, R | 1 |
| Berrevoets, CA; Brinkmann, AO; Trapman, J; Umar, A | 1 |
| Cardi, A; Di Silverio, F; Sciarra, A | 1 |
| Chang, LS; Chang, YH; Chen, KK; Chung, HJ; Hsu, YS; Huang, WJ; Kuo, JY; Lin, AD; Lin, AT; Wu, HH | 1 |
| Collette, L; de Reijke, TM; Debois, M; Kurth, KH; Mattelaer, J; Pavone-Macaluso, M; Schröder, FH; van Velthoven, RF; Whelan, P | 1 |
| Lotti, T; Montironi, R; Polito, M; Prezioso, D | 3 |
| Gardiner, RA; Green, HJ; Headley, BC; Mactaggart, PN; Nicol, DL; Pakenham, KI; Swanson, CE; Watson, RB; Yaxley, J | 1 |
| Jänne, OA; Kang, Z; Palvimo, JJ | 1 |
| Collette, L; Debois, M; Fosså, SD; Hoekstra, W; Karthaus, PP; Kurth, KH; Schröder, FH | 1 |
| Bai, C; Chen, F; Freedman, L; Gambone, C; Harada, S; Kasparcova, V; Knecht, K; Leu, C; Reszka, A; Rutledge, SJ; Scafonas, A; Schmidt, A; Vogel, R; Zhang, H | 1 |
| MacBride, MM; Muddana, SS; Peterson, BR; Price, AM | 1 |
| Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N | 1 |
| Ahamed, E; Bissett, D | 1 |
| Benney, M; Gillatt, DA; Okeke, AA; Sugiono, M; Winkler, MH | 1 |
| Eckardt, KU; Effert, P; Grimm, MO; Kurtz, A; Voegeli, TA | 1 |
| Debré, B; Delongchamps, NB; Peyromaure, M; Zerbib, M | 1 |
| Appu, S; Grills, RJ; Lawrentschuk, N; Neerhut, G | 1 |
| Bloomfield, DJ; Edginton, TL; Jenkins, VA; Shilling, VM | 1 |
| Akinmade, D; Brodie, A; Goloubeva, O; Hamburger, AW; Jelovac, D; Nakanishi, T; Ross, DD; Wang, XW; Yu, MH; Zhang, Y | 1 |
| Berthelet, E; Lee, KW; Liu, M; Pickles, T; Truong, PT | 1 |
| Costantini, A; Di Silverio, F; Serio, M | 1 |
| Chen, KC; Chyau, CC; Hsieh, CL; Hsieh, HM; Huang, CN; Peng, CC; Peng, CH; Peng, RY; Wang, HE | 1 |
| Floriani, I; Torri, V | 1 |
| Abdulkadir, SA; Eltoum, IA; Yang, SZ | 1 |
| Cecchini, MG; Klima, I; Peternac, D; Studer, UE; Thalmann, GN | 1 |
| Bruchovsky, N; Crook, J; Gleave, ME; Goldenberg, SL; Klotz, L; Ludgate, C; Malone, S; Morris, WJ | 1 |
| Deutsch, M; Dourakis, SP; Kafiri, G; Koudouras, D; Savidou, I; Soultati, AS | 1 |
| Bach, T; Blana, A; Ganzer, R; Rössler, W; Wieland, WF | 1 |
| Bruchovsky, N; Crook, J; Goldenberg, SL; Klotz, L | 1 |
| Baniahmad, A; Hong, W; Moehren, U; Papaioannou, M; Reeb, CA | 1 |
| Hara, S; Hyochi, N; Isaacs, JT; Ishioka, J; Kageyama, Y; Kihara, K; Singh, P; Urushibara, M | 1 |
| de Vries, CS; Farmer, RD; Langley, SE; Seaman, HE | 1 |
| Bosland, MC; Johnson, WD; Lubet, RA; McCormick, DL; Steele, VE | 1 |
| Bosland, MC; Haryu, TM; Johnson, WD; Lubet, RA; McCormick, DL; Steele, VE | 1 |
| Costa, J; Miquel, M; Ojanguren, I; Planas, R; Soler, A; Vaqué, A | 1 |
| Szendröi, Z | 1 |
| Eaton, AC; McGuire, N | 1 |
| Allhoff, E; Heising, J | 1 |
| Kawai, T; Kusuyama, H; Takahashi, T; Washizuka, M | 1 |
| Carlström, K; Varenhorst, E; Wallentin, L | 1 |
| Isaacs, JT | 1 |
| Bracci, U; Concolino, G; Conti, C; Di Silverio, F; Ferraro, F; Margiotta, G; Marocchi, A; Tenaglia, R | 1 |
| Bosland, MC; Kroes, R; Prinsen, MK | 1 |
| Aakvaag, A; Nissen-Meyer, R; Sander, S | 1 |
| Schroeder, FH | 1 |
| Büller, HR; Dabhoiwala, NF; Henny, CP; ten Cate, H; ten Cate, JW | 1 |
| Jacobi, GH; Wenderoth, UK | 1 |
| Allen, JM; Bloom, SR; Kerle, D; O'Shea, JP; Smith, C; Williams, G; Yeo, T | 1 |
| Giuliani, L | 1 |
| Carlström, K; Larsson, L; Tiselius, HG; Varenhorst, E | 1 |
| Becker, H; Düsterberg, B; Klosterhalfen, H | 1 |
| Karlberg, BE; Varenhorst, E; Wallentin, L; Wranne, B | 1 |
| Risberg, B; Varnehorst, E; Wallentin, L | 1 |
| Karlberg, BE; Risberg, B; Varenhorst, E; Wallentin, L; Wranne, B | 1 |
| Brosig, W; Hantelmann, W; Rost, A; Schmidt-Gollwitzer, M | 1 |
| Holub, G; Lunglmayr, G; Spona, J | 1 |
| Varenhorst, E; Wallentin, L | 2 |
| Bruchovsky, N; Gleave, ME; Goldenberg, SL; Jones, EC; Sullivan, LD | 1 |
| Aus, G; Busch, C; de la Torre, M; Elvin, A; Häggman, M; Hellström, M; Pedersen, K; Stege, R; Tisell, A; Wijkström, H | 1 |
| Aus, G; Brändstedt, S; de la Torre, M; Häggman, M; Hugosson, J; Pedersen, K | 1 |
| Cooper, EH; Purves, D; Whelan, P | 1 |
| Akakura, K; Bruchovsky, N; Gleave, ME; Goldenberg, SL; Sullivan, LD | 1 |
| Gillatt, D; Peters, TJ; Reynard, JM | 1 |
| Aus, G | 1 |
| Chanson, P; Schaison, G | 1 |
| Akakura, K; Bruchovsky, N; Buckley, AR; Goldenberg, SL; Rennie, PS; Sullivan, LD | 1 |
| Akakura, K; Bruchovsky, N; Goldenberg, SL; Rennie, PS | 1 |
| Chisholm, GD; Love, C; Paul, AB | 1 |
| Biordi, L; Bologna, M; Festuccia, C; Muzi, P; Vicentini, C | 1 |
| Kumanov, Kh; Tsvetkov, M | 1 |
| Neumann, F | 1 |
| Culine, S; Droz, JP; Elias, D; Kattan, J; Spatz, A; Terrier-Lacombe, MJ | 1 |
| Govindan, MV; Koutsilieris, M; Pagé, N; Warriar, N | 1 |
| Bernheim, J; Hirsch, D; Kovatz, S; Shenkman, L | 1 |
| Peetermans, C; Roux, E | 1 |
| Mast, P; Oosterlinck, W | 1 |
| Carloni, G; Crinò, L; Natalini, G; Roila, F | 1 |
| Schröder, FH | 4 |
| Robinson, MR | 4 |
| De Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, FH; Studer, UE; Sylvester, R | 1 |
| Berrevoets, CA; Mulder, E; Veldscholte, J | 1 |
| Jørgensen, LH; Jørgensen, T; Tveter, KJ | 1 |
| Heathcote, PS; Kateley, GD; Lloyd, S; Nicol, DL | 1 |
| Bolton, CH; Chadwick, D; Downs, LG; Gillatt, DA; Gingell, JC; Hopton, MI | 1 |
| McLeod, DG | 1 |
| Denis, L | 2 |
| Matzkin, H; Soloway, MS | 1 |
| Battisti, E; Fattorini, L; Fioravanti, A; Giordano, N; Magaro, L; Marcolongo, R; Marcucci, P | 1 |
| Danielsen, HE; Jørgensen, T; Kaalhus, O; Müller, C; Tveter, KJ | 1 |
| de Pauw, M; Newling, DW; Richards, B; Robinson, MR; Smith, PH; Sylvester, R | 1 |
| Michna, H; Schneider, MR; Vollmer, G | 1 |
| Bruchovsky, N; Gleave, ME; Goldenberg, SL; Sullivan, LD | 1 |
| Barkin, J; Bullock, MJ; Chin, J; Fradet, Y; Goldenberg, SL; Jewett, MA; Klotz, LH; Laplante, S; Mador, D; Paquin, JM; Srigley, J | 1 |
| Acar, O; Goldschmidt, AJ; Tunn, UW | 1 |
| Baisi, B; Castagnetti, G; Dotti, A; Ferrari, G; Ferrari, P | 1 |
| Abrahamsson, PA; Ahlgren, G; Aus, G; Hugosson, J; Lundberg, S; Pedersen, K; Schain, M; Schelin, S | 1 |
| Brändstedt, S; Busch, C; Häggman, M; Hellström, M; Wester, K | 1 |
| Azmatullah, S; Fellows, GJ; Gingell, JC; O'Boyle, PJ; Thorpe, SC | 1 |
| Collins, BJ; Murphy, BJ | 1 |
| Kumanov, Kh; Mladenov, D; Tsvetkov, M | 1 |
| Berges, RR; Hinkel, A; Pannek, J; Schulze, H; Senge, T | 1 |
| Walsh, PC | 1 |
| Brändstedt, S; Busch, C; Hellström, M; Ranepall, P; Wester, K | 1 |
| Andert, S; Dürer, A; Haberl, I; Hamilton, G; Holub, S; Theyer, G; Theyer, U | 1 |
| Bernier, J; Bolla, M; Collette, L; Dubois, JB; Gil, T; Gonzalez, D; Kuten, A; Mirimanoff, RO; Pierart, M; Sternberg, C; Storme, G; Warde, P | 1 |
| Atahan, O; Kayigil, O; Metin, A | 1 |
| Orhan, D; Ozdiler, E; Sak, SD; Tulunay, O; Yaman, O | 1 |
| Boyd, PJ; Dearnaley, DP; Gadd, J; Hetherington, JW; Horwich, A; Huddart, RA; Whelan, P | 1 |
| Goldenberg, SL; Klotz, LH; Rabbani, F | 1 |
| de Voogt, H; Denis, L; Sylvester, RJ | 1 |
| de Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, FH; Studer, U; Sylvester, R | 1 |
| De Giovanni, L; Menchinelli, P; Meneschincheri, M; Ronzoni, G | 1 |
| Kool, JC | 1 |
| Castaldi, F; Covotta, L; Ferrazza, P; Lombardi, A; Midiri, G; Tesoriere, A; Urbano, V | 1 |
| Bonnet, P | 1 |
| Chang, C; Miyamoto, H; Wilding, G; Yeh, S | 1 |
| Boccardo, F; Brune, D; Bruynseels, J; De Porre, P; Debruyne, FJ; Denis, L; Fradet, Y; Janssens, M; Johansson, JE; Marberger, JM; Murray, R; Rassweiler, J; Tyrrell, C; Vangeneugden, T | 1 |
| André, J; Foury, O; Joly-Pharaboz, MO; Nicolas, B | 1 |
| Baniel, J; Flex, D; Sella, A; Sulkes, A | 1 |
| Fournier, G; Valéri, A | 1 |
| Bosland, MC; Kelloff, GJ; Lubet, RA; McCormick, DL; Rao, KV; Steele, VE | 1 |
| Bolla, M | 1 |
| Barkin, J; Chetner, M; Chin, J; Fradet, Y; Goldenberg, SL; Jewett, M; Klotz, LH; Laplante, S | 1 |
| Chertin, B; Farkas, A; Lindenberg, T; Spitz, IM | 1 |
| Bosland, MC; Johnson, WD; Kelloff, GJ; Lubet, RA; McCormick, DL; Rao, KV; Steele, VE | 1 |
| Chen, J; Kao, JH; Lai, MK; Liu, CM; Pu, YS | 1 |
| Friedman, G; Lamoureux, E; Sherker, AH | 1 |
| A'Hern, R; Hardy, J; Huddart, R; Richards, M; Stone, P | 1 |
| Bruchovsky, N; Gleave, ME; Goldenberg, SL; Jones, EC; La Bianca, SE; Sullivan, LD | 1 |
| Jones, GR; Lyng, FM; Rommerts, FF | 1 |
| Cervenákov, I; Chovan, D; Jancár, M; Kopecný, M; Mal'a, M | 1 |
| Gleave, M; Goldenberg, SL; Klotz, L | 1 |
| Candas, B; Labrie, F | 1 |
| Dearnaley, DP; Gapinski, CJ; Husband, JE; Leach, MO; MacVicar, AD; Padhani, AR; Parker, GJ; Suckling, J | 1 |
| Di Chiro, C; Di Silverio, F; Sciarra, A | 1 |
| de Matteis, A; Di Paolo, B; Franco, G; Guidi, A; Revoltella, RP | 1 |
| Bissett, JD; Macdonald, AG | 1 |
| Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ | 1 |
| Gennari, C; Geraci, S; Giordano, N; Nardi, P; Santacroce, C | 1 |
| Abbar, M; Ameur, A; el Alami, M; el Mostarchid, B; Jira, H; Touiti, D | 1 |
| Dearnaley, DP; Horwich, A; Huddart, RA; Norman, AR; Parker, CC | 1 |
| Hermabessière, J | 1 |
| Kastelan, M; Kraljić, I; Tarle, M | 1 |
| Alivizatos, G; Constantinides, C; Dimopoulos, C; Mitropoulos, D | 1 |
| Gobet, DA; Hauri, D; Knönagel, H | 1 |
| Mukamel, E; Nussbaum, B; Servadio, C | 1 |
| de Voogt, HJ | 2 |
| Bosland, MC; Fiala, E; Kroes, R; Prinsen, MK; Rivenson, A; Silverman, J; Weisburger, JH; Williams, GM | 1 |
| Schmeller, N | 1 |
| Aubert, J; Bon, D; Dore, B; Irani, J | 1 |
| Bonnesen, T; Frimodt-Møller, C; Nilsson, T; Ostri, P | 1 |
| García Vicente, C; Lobato Encinas, JJ; Megías Garrigos, J; Mira Llinares, A; Pelluch Auladell, A; Pérez-Llorca, LA; Romero Pérez, P | 1 |
| Radoś, N; Tarle, M | 1 |
| Aubert, J; Aubert, MN; Dore, B; Irani, J | 1 |
| Bruchovsky, N; Goldenberg, SL | 1 |
| Hamid, S; Parys, BT; Thomson, RG | 1 |
| Fidison, A; Radesa, F; Radio, C; Zafy, A | 1 |
| Huhtaniemi, I; Parvinen, M; Rannikko, S; Venho, P | 1 |
| Antoni, M; Botta-Fridlund, D; Bourlière, M; Gauthier, A; Maillot, A; Toullec, J | 1 |
| el Etreby, MF; Habenicht, UF; Neumann, F | 1 |
| Gaer, JA; Keane, PF; Ohri, SK | 1 |
| Bosland, MC; Prinsen, MK | 1 |
| Braude, S; Taylor, H | 1 |
| Blake, JC; Dooley, JS; McIntyre, N; Sawyerr, AM; Scheuer, PJ | 1 |
| Abel, PD; Asopa, R; Smith, C; Williams, G | 1 |
| Abad Menor, F; Arnaiz Esteban, F; Espuela Orgaz, R; Martínez Pérez, E; Nogueras Gimeno, MA; Pérez Arbej, JA | 1 |
| Schulze, H; Senge, T | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F | 1 |
| Aubert, J; Dore, B; Irani, J; Orget, J | 1 |
| Concolino, G; Di Silverio, F; Sciarra, F; Toscano, V | 1 |
| Bormacher, K; Neumann, F; Radlmaier, A | 1 |
| Becker, M; Goldschmidt, AJ; Peter, K; Tunn, UW | 1 |
| Bolt, J; Mulder, E; Schuurmans, AL; Veldscholte, J | 1 |
| De Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, F; Studer, U; Sylvester, R | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F; Tenaglia, R | 1 |
| Boronat, F; Broseta, E; Gallego, J; Jiménez-Cruz, JF; Llopis, B; Osca, JM | 1 |
| Moffat, LE | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F; Serio, M | 1 |
| Arbusow, V; Bojar, H; Fittler, F; Klobeck, HG; Schulz, P; Wolf, D | 1 |
| Graff, J; Nieschlag, E; Schürmeyer, T; Senge, T | 1 |
| Cusan, L; Labrie, C; Labrie, F; Lapointe, S; Plante, M | 1 |
| Labrie, F; Lapointe, S; Plante, M | 1 |
| Namer, M | 1 |
| Hendriksen, ON; Jansen, JE | 1 |
| de Pauw, M; de Voogt, HJ; Pavone-Macaluso, M; Smith, PH; Suciu, S; Sylvester, R | 1 |
| Schaison, G | 1 |
| Green, NA; Harrison, BD | 1 |
| Tunn, UW | 1 |
| Barasolo, E; de Pauw, M; de Voogt, HJ; Lardennois, B; Pavone-Macaluso, M; Schröder, FH; Smith, PH; Suciu, S; Sylvester, R; Viggiano, G | 1 |
| Waxman, J | 1 |
| Milsted, RA | 1 |
| Cordeschi, G; Francavilla, S; Galassi, P; Miano, L; Paradiso Galatioto, G; Properzi, G; Vicentini, C | 1 |
| Furr, BJ | 1 |
| Bonini, R; Papineschi, F; Pistolisi, D; Spremolla, G | 1 |
| Daricello, G; Pavone, C; Pavone-Macaluso, M; Romano, C; Serretta, V | 1 |
| de Jong, FH; Lamberts, SW; Uitterlinden, P | 1 |
| Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G | 1 |
| Sogani, PC; Whitmore, WF | 1 |
| Albert, JD; Geller, J | 1 |
| Høisaeter, PA; Rasmussen, F | 1 |
| de Pauw, M; de Voogt, HJ; Pavone-Macaluso, M; Smith, PH; Suciu, S | 2 |
| Hofmann, W; Langkopf, B | 1 |
| Bolton, C; Gingell, JC; Hartog, M; Kadow, C; Paisey, RB | 1 |
| Cunningham, GR; Shao, TC; Tindall, DJ | 1 |
| Soloway, MS | 1 |
| Barasolo, E; de Pauw, M; de Voogt, HJ; Lardennois, B; Pavone-Macaluso, M; Sylvester, R; Viggiano, G | 1 |
| Fair, WR | 1 |
| de Voogt, HJ; Hoogendijk, E | 1 |
| Berns, EM; de Boer, W; Mulder, E | 1 |
| Amselgruber, W; Hartmann, RW; Schneider, MR; Sinowatz, F | 1 |
| Di Silverio, F; Sciarra, F | 1 |
| Boccon-Gibod, L; Dugue, MA; Laudat, MH; Steg, A | 1 |
| Bolt, J; Brinkmann, AO; de Boer, W; Kuiper, GG; Mulder, E; van Steenbrugge, GJ | 1 |
| Isaacs, J; Schulze, H; Senge, T | 1 |
| Chadha, DR; de Jong, FH; de Voogt, HJ; Debruyne, FM; Karthaus, HF; Klijn, JG; Lock, TM; Matroos, AW; Schroeder, FH | 1 |
| Fair, WR; Sogani, PC | 1 |
| Eland, D; Hackeng, WH; Mulder, H; Schopman, W | 1 |
| Claes, HI; Vandenbussche, L; Vereecken, RL | 1 |
| Dupront, A; Meyer, BH; Pottier, J; Tremblay, D | 1 |
| Saborowski, J; Senge, T; Tunn, UW; Weiglein, W | 1 |
| Beurton, D; Cukier, J; Davody, P; Grall, J | 1 |
| Barasolo, E; De Pauw, M; de Voogt, H; Ingargiola, GB; Lardennois, B; Pavone-Macaluso, M; Sylvester, R; Viggiano, G | 1 |
| Maier, U | 2 |
| el Etreby, MF; Habenicht, UF; Neumann, F; Schröder, H | 1 |
| al-Abadi, H; Borgmann, V; Nagel, R | 1 |
| Debruyne, FM | 1 |
| Ferro, MA; Heinemann, D; Smith, PJ; Symes, MO | 1 |
| Hermabessière, J; Tauveron, I | 1 |
| Arvis, G; Tobelem, G | 1 |
| deVoogt, HJ; Pavone-Macaluso, M; Schröder, FH; Sylvester, R | 1 |
| Bruchovsky, N; Coppin, CM; Goldenberg, SL; Rennie, PS | 1 |
| Hjertberg, H; Kågedal, B; Nordenskjöld, B; Svensson, M; Varenhorst, E | 1 |
| Bouffioux, C | 1 |
| Bollack, C; Rougeron, G | 1 |
| Alioth, H; Müller, J; Senn, E | 1 |
| Alund, G; Varenhorst, E | 1 |
38 review(s) available for cyproterone acetate and Cancer of Prostate
| Article | Year |
|---|---|
[Hormonal treatment in prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms | 2013 |
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Tosyl Compounds | 2004 |
Monotherapy in advanced prostate cancer: an overview.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Dihydrotestosterone; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Nitriles; Orchiectomy; Palliative Care; Progesterone Congeners; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone; Tosyl Compounds | 2004 |
Cyproterone acetate in the therapy of prostate carcinoma.
Topics: Androgen Antagonists; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 2005 |
Hepatotoxicity induced by cyproterone acetate: a report of three cases.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Humans; Liver Diseases; Male; Prostatic Neoplasms | 2006 |
[Hormonal treatment of cancer of the prostate: review and present status].
Topics: Administration, Oral; Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Confidence Intervals; Cyproterone Acetate; Disease Models, Animal; Dogs; Estrogens; Gonadotropin-Releasing Hormone; Humans; Male; Meta-Analysis as Topic; Multicenter Studies as Topic; Nitriles; Orchiectomy; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Testosterone; Time Factors; Tosyl Compounds | 2007 |
New forms and future perspectives in endocrine treatment of prostatic carcinoma.
Topics: Aminoglutethimide; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Estrogen Antagonists; Flutamide; Hormones; Humans; Male; Pituitary Hormone-Releasing Hormones; Prolactin; Prostatic Neoplasms | 1984 |
The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research.
Topics: Animals; Cyproterone Acetate; Female; Humans; Hyperandrogenism; Male; Molecular Structure; Prostatic Neoplasms; Sex Differentiation; Sexual Dysfunction, Physiological | 1994 |
Hepatocellular carcinoma during hormonotherapy for prostatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cyproterone Acetate; Humans; Liver Neoplasms; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Triptorelin Pamoate | 1994 |
Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 1994 |
Cyproterone acetate--mechanism of action and clinical effectiveness in prostate cancer treatment.
Topics: Animals; Cyproterone Acetate; Female; Humans; Male; Mammary Neoplasms, Experimental; Prostate; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1993 |
Antiandrogenic drugs.
Topics: Androgen Receptor Antagonists; Anilides; Cyproterone Acetate; Diethylstilbestrol; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Megestrol; Megestrol Acetate; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1993 |
Prostate cancer. Primary hormonal treatment.
Topics: Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Dihydrotestosterone; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Orchiectomy; Patient Participation; Prostate; Prostatic Neoplasms; Receptors, Androgen; Testosterone | 1993 |
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 1993 |
The place and the results of monotherapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Antiandrogens as monotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
Fatal fulminant hepatic failure due to cyproterone acetate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Fatal Outcome; Hepatic Encephalopathy; Humans; Liver; Male; Neoplasm Staging; Prostatic Neoplasms | 1999 |
Neoadjuvant hormone therapy: the Canadian trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Canada; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
[Cyproterone acetate: cardiovascular tolerance].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms; Risk Factors | 1992 |
The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 1992 |
[Exophthalmos caused by orbital metastasis of prostatic carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Exophthalmos; Humans; Male; Orbital Neoplasms; Orchiectomy; Palliative Care; Prostatic Neoplasms | 1991 |
[Prostatic cancer before the age of 50--report of 7 cases].
Topics: Age Factors; Antineoplastic Agents; Biopsy; Cyproterone Acetate; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Urography | 1991 |
Use of cyproterone acetate in prostate cancer.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 1991 |
Cancer of the prostate. Mechanisms of action of antiandrogens.
Topics: Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Rats; Testosterone | 1991 |
Antiandrogenic substances in the management of prostatic cancer.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Prostatic Neoplasms | 1990 |
Hot flushes: mechanism and prevention.
Topics: Androgen Antagonists; Body Temperature Regulation; Climacteric; Clonidine; Cyproterone; Cyproterone Acetate; Estrogens; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1990 |
Cyproterone acetate as monotherapy in prospective randomized trials.
Topics: Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Humans; Male; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1990 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
[Volumetric and structural changes of prostatic carcinoma under hormonal treatment].
Topics: Aged; Aged, 80 and over; Carcinoma; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Ultrasonography | 1990 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Puberty, Precocious; Skin Diseases; Spironolactone | 1988 |
Cyproterone acetate in the management of prostatic cancer.
Topics: Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms; Random Allocation | 1989 |
Initiation of LHRH monotherapy for prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms | 1989 |
Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Megestrol; Megestrol Acetate; Prostatic Neoplasms | 1988 |
Adrenal androgen blockade in relapsed prostate cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Castration; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Male; Megestrol; Megestrol Acetate; Neoplasm Metastasis; Prognosis; Prostate; Prostatic Neoplasms | 1985 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Estrogens; Flutamide; Glucocorticoids; Humans; Ketoconazole; Male; Megestrol; Megestrol Acetate; Orchiectomy; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Spironolactone; Time Factors | 1987 |
Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
Topics: Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Female; Flutamide; Glucuronidase; Gonadotropin-Releasing Hormone; Guinea Pigs; Kidney; Male; Mice; Prostatic Neoplasms; Rats; Sex Differentiation; Time Factors | 1988 |
Is there a best endocrine management of prostatic carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Prostatic Neoplasms | 1988 |
[LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
Topics: Androgen Antagonists; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Dogs; Drug Therapy, Combination; Flutamide; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Cell Surface; Receptors, LHRH | 1985 |
81 trial(s) available for cyproterone acetate and Cancer of Prostate
| Article | Year |
|---|---|
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy.
Topics: Aged; Androgen Antagonists; Cyproterone Acetate; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Treatment Outcome | 2021 |
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Disease Progression; Europe; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Sexuality; Survival Rate; Time Factors; Triptorelin Pamoate | 2014 |
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial.
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 2014 |
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cyproterone Acetate; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Gonadotropin-Releasing Hormone; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk Assessment; Survival Analysis | 2009 |
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
Topics: Adenocarcinoma; Androgen Antagonists; Autonomic Agents; Cyclohexanols; Cyproterone Acetate; Double-Blind Method; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; Male; Medroxyprogesterone Acetate; Prospective Studies; Prostatic Neoplasms; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Canada; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Europe; Fractures, Bone; Goserelin; Humans; Israel; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Prostatic Neoplasms; Risk Assessment; Russia; Time Factors; Treatment Outcome | 2010 |
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cognition Disorders; Cyproterone Acetate; Drug Combinations; Goserelin; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms | 2002 |
Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyproterone Acetate; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Treatment Outcome | 2002 |
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis | 2003 |
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.
Topics: Androgen Antagonists; Chemotherapy, Adjuvant; Cyproterone Acetate; Follow-Up Studies; Humans; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms | 2003 |
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate | 2004 |
Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cyproterone Acetate; Delayed-Action Preparations; Humans; Leuprolide; Male; Middle Aged; Preoperative Care; Prostatectomy; Prostatic Neoplasms | 2004 |
Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cognition Disorders; Cyproterone Acetate; Goserelin; Humans; Leuprolide; Male; Prostatic Neoplasms; Quality of Life; Sexual Dysfunction, Physiological; Stress, Psychological | 2004 |
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Prostatic Neoplasms; Survival Rate; Time Factors | 2004 |
Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cyproterone Acetate; Goserelin; Humans; Injections, Subcutaneous; Male; Nitriles; Pain; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Castration; Cyproterone Acetate; Humans; Leuprolide; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2005 |
Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cognition Disorders; Cyproterone Acetate; Goserelin; Humans; Intelligence; Male; Memory Disorders; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prostatic Neoplasms; Quality of Life; Speech Disorders; Surveys and Questionnaires | 2005 |
Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Topics: Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Canada; Cyproterone Acetate; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2006 |
Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Testosterone | 2007 |
Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial.
Topics: Aged; Androgen Antagonists; Castration; Climacteric; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Double-Blind Method; Flushing; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1983 |
Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study.
Topics: Adenocarcinoma; Aged; Castration; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Humans; Male; Prednisone; Prostatic Neoplasms; Random Allocation | 1982 |
Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Topics: Castration; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Estramustine; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Mitomycin; Mitomycins; Procarbazine; Prostatic Neoplasms; Random Allocation; Vinblastine; Vindesine | 1984 |
Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cyproterone Acetate; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone; Time Factors | 1996 |
Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancer.
Topics: Biomarkers, Tumor; Chemotherapy, Adjuvant; Cyproterone Acetate; Humans; Male; Middle Aged; Preoperative Care; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Time Factors; Triptorelin Pamoate | 1994 |
Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Diethylstilbestrol; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Time Factors | 1995 |
Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Cyproterone Acetate; Diethylstilbestrol; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pituitary Gland; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Survival Rate; Testosterone | 1993 |
A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Follow-Up Studies; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1993 |
Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone Acetate; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1993 |
Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2.
Topics: Bone Neoplasms; Cyproterone Acetate; Double-Blind Method; Humans; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1993 |
Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
Topics: Androgen Antagonists; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Cyproterone Acetate; Disease Progression; Follow-Up Studies; Humans; Male; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Radionuclide Imaging; Severity of Illness Index | 1995 |
The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of t
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate; Time Factors | 1995 |
Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Protocols; Confidence Intervals; Cyproterone Acetate; Diethylstilbestrol; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Testosterone | 1996 |
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Cyproterone Acetate; Humans; Male; Middle Aged; Prospective Studies; Prostatectomy; Prostatic Neoplasms | 1996 |
Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 1996 |
Combination treatment versus LHRH alone in advanced prostatic cancer.
Topics: Age Distribution; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1996 |
The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Blood Loss, Surgical; Chemotherapy, Adjuvant; Cyproterone Acetate; Humans; Male; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone; Time Factors; Triptorelin Pamoate | 1996 |
A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Goserelin; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Safety | 1996 |
Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyproterone Acetate; Humans; Immunohistochemistry; Male; Ploidies; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1997 |
Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyproterone Acetate; Drug Administration Schedule; Goserelin; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tissue Polypeptide Antigen | 1997 |
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cyproterone Acetate; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 1997 |
Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyproterone Acetate; Humans; Logistic Models; Male; Multivariate Analysis; Neoplasms, Hormone-Dependent; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1998 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Combined Modality Therapy; Cyproterone Acetate; Disease-Free Survival; Flutamide; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Survival Rate | 1998 |
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis o
Topics: Acid Phosphatase; Administration, Intranasal; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Cause of Death; Cyproterone Acetate; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Subcutaneous; Male; Middle Aged; Orchiectomy; Pain Measurement; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1998 |
Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyproterone Acetate; Delayed-Action Preparations; Diagnosis, Differential; Disease-Free Survival; Drug Administration Schedule; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostatectomy; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms | 1998 |
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Castration; Cyproterone Acetate; Diethylstilbestrol; Doxorubicin; Epirubicin; Estramustine; Flutamide; Humans; Imidazoles; Male; Medroxyprogesterone Acetate; Methotrexate; Mitomycin; Neoplasms, Hormone-Dependent; Procarbazine; Prostatic Neoplasms; Vindesine | 1998 |
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 1998 |
Antiandrogen withdrawal syndrome with cyproterone acetate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome | 1998 |
Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cyproterone Acetate; Diagnosis, Differential; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms | 1999 |
Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Flutamide; Humans; Male; Neoplasm Staging; Prostatic Neoplasms | 1999 |
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.
Topics: Androgen Antagonists; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease Progression; Humans; Male; Preoperative Care; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 1999 |
Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Patient Care Planning; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2002 |
Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Orchiectomy; Palliative Care; Prospective Studies; Prostatic Neoplasms | 1991 |
Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenedione; Cyproterone; Cyproterone Acetate; Dexamethasone; Humans; Hydrocortisone; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone | 1990 |
Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Topics: Aged; Androgen Antagonists; Anilides; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1990 |
Antiandrogens: clinical applications.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic; Female; Flutamide; Hirsutism; Humans; Male; Prostatic Neoplasms; Spironolactone | 1990 |
Cyproterone acetate as monotherapy in prospective randomized trials.
Topics: Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Humans; Male; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1990 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 1990 |
Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyproterone Acetate; Europe; Humans; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Risk Factors | 1990 |
Incidental prostatic carcinoma: four-year follow-up after treatment with cyproterone acetate.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; DNA, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Retrospective Studies | 1990 |
Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
Topics: Androgen Antagonists; Breast; Buserelin; Cardiovascular Diseases; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Goserelin; Humans; Male; Prospective Studies; Prostatic Neoplasms | 1990 |
Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1990 |
Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.
Topics: Adult; Aged; Aged, 80 and over; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Europe; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Multicenter Studies as Topic; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Prostatic Neoplasms; Random Allocation; Statistics as Topic | 1989 |
Cyproterone acetate in the management of prostatic cancer.
Topics: Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms; Random Allocation | 1989 |
EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Europe; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Multicenter Studies as Topic; Prostatic Neoplasms; Random Allocation | 1989 |
Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1989 |
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Phosphoric Monoester Hydrolases; Prostatic Neoplasms; Random Allocation; Testosterone | 1988 |
The Scandinavian Prostatic Cancer Group.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Double-Blind Method; Humans; Male; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Random Allocation | 1985 |
Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer tria
Topics: Aged; Body Weight; Cardiovascular Diseases; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Europe; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Nitrogen Mustard Compounds; Prostatic Neoplasms; Random Allocation; Time Factors | 1986 |
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological
Topics: Aged; Bone Neoplasms; Carcinoma; Cardiovascular Diseases; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Europe; Follow-Up Studies; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Prostatic Neoplasms; Random Allocation | 1986 |
Treatment of advanced prostatic cancer with anti-androgens alone and a combination of anti-androgen with anti-prolactin--a pilot study.
Topics: Aged; Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Ergolines; Humans; Lisuride; Male; Middle Aged; Neoplasm Staging; Prolactin; Prostatic Neoplasms | 1986 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Estrogens; Flutamide; Glucocorticoids; Humans; Ketoconazole; Male; Megestrol; Megestrol Acetate; Orchiectomy; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Spironolactone; Time Factors | 1987 |
Clinical experience with cyproterone acetate in a randomised and in an open trial.
Topics: Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms; Random Allocation | 1987 |
Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
Topics: Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Prostatic Neoplasms | 1987 |
Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1987 |
EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Clinical Protocols; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Europe; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1988 |
Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
Topics: Antineoplastic Agents; Carcinoma; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Drug Administration Schedule; Estramustine; Europe; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Prostatic Neoplasms; Random Allocation | 1988 |
Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
Topics: Aged; Aged, 80 and over; Biopsy, Needle; Buserelin; Carcinoma; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Cytophotometry; DNA, Neoplasm; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Staging; Prostate; Prostatic Neoplasms; Remission Induction | 1988 |
Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Topics: Aged; Buserelin; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Humans; Lymphatic Metastasis; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Netherlands; Orchiectomy; Prostatic Neoplasms; Remission Induction; Time Factors | 1988 |
Is there a best endocrine management of prostatic carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Prostatic Neoplasms | 1988 |
Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Heart; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Prostatic Neoplasms | 1988 |
Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
Topics: Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Time Factors | 1988 |
169 other study(ies) available for cyproterone acetate and Cancer of Prostate
| Article | Year |
|---|---|
First synthesis of separable isomeric testosterone dimers showing differential activities on prostate cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Isomerism; Male; Models, Molecular; Prostatic Neoplasms; Testosterone | 2010 |
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Proliferation; Cell Survival; Databases, Factual; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Estrogen Receptor beta; Fluorescence Polarization; Fluorescence Resonance Energy Transfer; Humans; Hydrazines; Male; Models, Molecular; Nuclear Receptor Coactivators; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Receptors, Glucocorticoid; Receptors, Progesterone; Structure-Activity Relationship | 2012 |
Synthesis and preliminary in vitro biological evaluation of 7α-testosterone-chlorambucil hybrid designed for the treatment of prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chlorambucil; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Molecular Conformation; Prostatic Neoplasms; Structure-Activity Relationship; Testosterone | 2013 |
Innovative C
Topics: Androstenedione; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cytochrome P-450 CYP3A; Dimerization; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Recombinant Proteins; Structure-Activity Relationship; Testosterone; Tumor Cells, Cultured | 2021 |
Discovery of
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Binding Sites; Cell Proliferation; Gene Expression; Humans; Male; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Prostatic Neoplasms; Protein Transport; Receptors, Androgen; Structure-Activity Relationship; Sulfonamides; Xenograft Model Antitumor Assays | 2022 |
Fatal acute liver failure induced by cyproterone acetate: A new case.
Topics: Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Fatal Outcome; Humans; Liver Failure, Acute; Male; Middle Aged; Prostatic Neoplasms | 2017 |
[Hepatotoxicity induced by cyproteron acetate in the prostate carcinoma treatment - a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Cyproterone Acetate; Humans; Liver Failure, Acute; Male; Prostatic Neoplasms | 2013 |
Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Humans; Jaundice; Liver; Male; Middle Aged; Outcome Assessment, Health Care; Prostatic Neoplasms; Risk Assessment; Severity of Illness Index | 2016 |
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
Topics: Apoptosis; Cyproterone Acetate; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Hormone Antagonists; Humans; Male; Mifepristone; Prostatic Neoplasms; Receptors, Glucocorticoid; Taxoids; Tumor Cells, Cultured | 2016 |
Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.
Topics: Androgens; Apoptosis; Cell Line, Tumor; Cyproterone Acetate; Gene Expression Regulation, Neoplastic; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP | 2017 |
Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Topics: Androgen Antagonists; Butadienes; Cell Line, Tumor; Cell Proliferation; Cyproterone Acetate; DNA-Binding Proteins; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; MAP Kinase Signaling System; Neoplastic Stem Cells; Nitriles; Nuclear Receptor Co-Repressor 2; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Repressor Proteins; Transcriptional Activation | 2009 |
GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Blotting, Western; Cell Line, Tumor; Cyproterone Acetate; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Leuprolide; Male; Prostatic Neoplasms; Receptors, LHRH; RNA, Messenger; Up-Regulation | 2009 |
Coactivator selective regulation of androgen receptor activity.
Topics: Androgens; Animals; Cell Line, Tumor; Cell Proliferation; Cyproterone Acetate; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Male; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 3; Prostatic Neoplasms; Receptors, Androgen; RNA, Long Noncoding; RNA, Untranslated; Substrate Specificity; Transcription Factors; Transcription, Genetic; Transcriptional Activation | 2009 |
Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Line, Tumor; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Humans; Hydrocortisone; Hydrophobic and Hydrophilic Interactions; Male; Mutation; Nitriles; Progesterone; Prostatic Neoplasms; Protein Structure, Secondary; Receptors, Androgen; Steroids; Structure-Activity Relationship; Tosyl Compounds | 2010 |
Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate.
Topics: Adenocarcinoma; Alkylating Agents; alpha-Tocopherol; Androgens; Animals; Antioxidants; Cyproterone Acetate; Disease Models, Animal; Drug Therapy, Combination; Male; Methylnitrosourea; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Rats; Rats, Wistar; Selenium Compounds; Selenomethionine; Testosterone; Vitamin E | 2010 |
Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.
Topics: Androgens; Anilides; Cell Line, Tumor; Chromatin; Cyproterone Acetate; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic | 2011 |
Is long-term androgen suppression right for everyone with locally advanced prostate cancer?
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Fractures, Bone; Goserelin; Humans; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Prostatic Neoplasms; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Ascorbic Acid; Bone Neoplasms; Catalase; Cyproterone Acetate; Erythrocytes; Goserelin; Humans; Lipid Peroxidation; Male; Middle Aged; Neoplasm Grading; Oxidative Stress; Prostatic Neoplasms; Protein Carbonylation; Sulfhydryl Compounds; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Vitamin E | 2011 |
Chemical castration for sexual offenders: physicians' views.
Topics: Castration; Cyproterone Acetate; Gonadotropin-Releasing Hormone; Humans; Male; Medroxyprogesterone Acetate; Physicians; Prostatic Neoplasms; Psychotherapy; Sex Offenses | 2013 |
Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145.
Topics: Androgen Antagonists; Androgens; Apoptosis; Cell Division; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Gene Expression; Humans; Male; Nerve Growth Factor; Prostatic Neoplasms; Receptor, Nerve Growth Factor; Receptors, Androgen; RNA, Messenger; Telomerase; Tumor Cells, Cultured | 2002 |
Improved prostate cancer treatment.
Topics: Androgen Antagonists; Combined Modality Therapy; Controlled Clinical Trials as Topic; Cyproterone Acetate; Goserelin; Humans; Male; Prostatic Neoplasms; United States | 2002 |
A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4.
Topics: Androgen Antagonists; beta Catenin; Cyproterone Acetate; Cytoskeletal Proteins; Humans; Ligands; Male; Prostatic Neoplasms; Protein Binding; Proto-Oncogene Proteins; Receptors, Androgen; Signal Transduction; TCF Transcription Factors; Trans-Activators; Transcription Factor 7-Like 2 Protein; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Wnt Proteins; Zebrafish Proteins | 2003 |
Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Binding, Competitive; Cell Line, Tumor; CHO Cells; Cricetinae; Cyproterone Acetate; Down-Regulation; Gene Expression Regulation; Ligands; Male; Metribolone; Mice; Mifepristone; Mutation; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 2; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Repressor Proteins; Transcription Factors; Transcription, Genetic; Transfection | 2004 |
Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prostatic Neoplasms; Time Factors | 2003 |
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Topics: Acetylation; Androgen Receptor Antagonists; Anilides; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyproterone Acetate; DNA Polymerase II; Enhancer Elements, Genetic; Gene Expression Regulation; Histones; Humans; Male; Methylation; Mifepristone; Nitriles; Nuclear Proteins; Nuclear Receptor Coactivator 2; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Arginine N-Methyltransferases; Receptors, Androgen; Tissue Kallikreins; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcription, Genetic | 2004 |
Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Topics: Adaptor Proteins, Signal Transducing; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Androstenediol; Androstenedione; Anilides; Animals; Breast Neoplasms; Carrier Proteins; Cell Division; Chlorocebus aethiops; COS Cells; Cyproterone Acetate; Dihydrotestosterone; Humans; Ligands; Macaca mulatta; Male; Mammary Tumor Virus, Mouse; Mice; Nerve Tissue Proteins; Nitriles; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, AMPA; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cyproterone Acetate; Dimerization; Humans; Ligands; Male; Mifepristone; Nandrolone; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship | 2004 |
Rhabdomyolysis in prostate cancer--caution in prescribing cyproterone acetate with statins.
Topics: Aged; Anticholesteremic Agents; Antineoplastic Agents; Cyproterone Acetate; Drug Interactions; Humans; Hypercholesterolemia; Male; Prostatic Neoplasms; Rhabdomyolysis; Simvastatin | 2004 |
Anemia under androgen deprivation: influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system.
Topics: Androgen Antagonists; Androgens; Anemia; Animals; Cyproterone Acetate; Erythropoietin; Flutamide; Hematopoiesis; Humans; Male; Orchiectomy; Prostatic Neoplasms; Rats; Rats, Wistar | 2005 |
Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience.
Topics: Aged; Androgen Antagonists; Cyproterone Acetate; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Time Factors | 2005 |
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Androgen Antagonists; Anilides; Animals; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyproterone Acetate; DNA Primers; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Male; Mice; Mice, SCID; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Receptor, ErbB-3; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Tosyl Compounds | 2005 |
Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Cyproterone Acetate; Diethylstilbestrol; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate; Time Factors | 2005 |
Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Disease Progression; Goserelin; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 1989 |
Antiandrogenic therapy can cause coronary arterial disease.
Topics: Aged; Androgen Antagonists; Apolipoprotein A-I; Apolipoprotein A-II; Biomarkers; Cholesterol, HDL; Coronary Disease; Cyproterone Acetate; Electrocardiography; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Risk Factors; Triglycerides | 2005 |
Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen-depleted environment.
Topics: Androgens; Animals; Cell Nucleus; Cyproterone Acetate; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Male; Mice; Mice, Nude; Orchiectomy; Prostatic Neoplasms; RNA Interference; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyproterone Acetate; DNA, Complementary; Goserelin; Humans; Male; Nitriles; Polymerase Chain Reaction; Prostate-Specific Antigen; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds | 2006 |
Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth.
Topics: Androgen Antagonists; Androgens; Cell Division; Cyproterone Acetate; Humans; Male; Oligonucleotide Array Sequence Analysis; Plasmids; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transfection | 2007 |
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone Acetate; Flutamide; Humans; Imidazolidines; Male; Models, Molecular; Mutagenesis, Site-Directed; Neoplasms, Hormone-Dependent; Nitriles; Plasmids; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Testosterone; Tosyl Compounds; Transcription, Genetic; Transfection | 2007 |
Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cohort Studies; Cyproterone Acetate; Databases as Topic; Family Practice; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Risk Factors; Severity of Illness Index; Survival Analysis; Thromboembolism; Venous Thrombosis | 2007 |
Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor.
Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Cyproterone Acetate; Dose-Response Relationship, Drug; Drug Synergism; Humans; Isoflavones; Male; Methylnitrosourea; Prostatic Neoplasms; Random Allocation; Rats; Rats, Wistar; Testosterone Propionate; Time Factors; Trypsin Inhibitor, Bowman-Birk Soybean | 2007 |
Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat.
Topics: Animals; Carcinogens; Cyproterone Acetate; Diet, Reducing; Dose-Response Relationship, Drug; Humans; Male; Methylnitrosourea; Prevalence; Prostatic Neoplasms; Rats; Rats, Wistar; Testosterone; Testosterone Propionate; Treatment Outcome; Weight Gain | 2007 |
Suspected cross-hepatotoxicity of flutamide and cyproterone acetate.
Topics: Acute Disease; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Drug Monitoring; Flutamide; Humans; Liver; Liver Function Tests; Male; Prostatic Neoplasms; Severity of Illness Index; Treatment Outcome | 2007 |
Gestagens in the management of prostatic carcinoma.
Topics: Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Humans; Male; Norethindrone; Prostatic Neoplasms; Receptors, Cell Surface; Testosterone | 1984 |
[Treatment and prognosis of prostate carcinoma. Actual standing (author's transl)].
Topics: Antineoplastic Agents; Castration; Cyproterone; Cyproterone Acetate; Estradiol Congeners; Humans; Male; Neoplasm Staging; Palliative Care; Prognosis; Prostatectomy; Prostatic Neoplasms | 1981 |
[Prostate cancer].
Topics: Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Estrogens; Humans; Male; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage | 1984 |
The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
Topics: Aged; Castration; Cyproterone; Cyproterone Acetate; Estrogens; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testis; Testosterone | 1982 |
Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
Topics: Adenocarcinoma; Animals; Castration; Cell Division; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Kinetics; Male; Neoplasms, Experimental; Prostatic Neoplasms; Rats | 1982 |
Steroid receptors and hormone responsiveness of human prostatic carcinoma.
Topics: Castration; Cell Nucleus; Cyproterone; Cyproterone Acetate; Cytosol; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Receptors, Steroid | 1982 |
Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone.
Topics: Adenocarcinoma; Animals; Carcinoma in Situ; Cocarcinogenesis; Cyproterone; Cyproterone Acetate; Male; Methylnitrosourea; Models, Biological; Neoplasm Metastasis; Neoplasms, Experimental; Nitrosourea Compounds; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Testosterone | 1983 |
Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma.
Topics: Aged; Antithrombin III; Castration; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Fibrinolysis; Humans; Male; Middle Aged; Prostatic Neoplasms | 1984 |
The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Topics: Adenocarcinoma; Buserelin; Castration; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone | 1984 |
[Treatment of prostatic cancer].
Topics: Adenocarcinoma; Aged; Brachytherapy; Cesium Radioisotopes; Cyproterone; Cyproterone Acetate; Estrogens; Gonadotropin-Releasing Hormone; Humans; Iridium; Lymph Node Excision; Male; Middle Aged; Orchiectomy; Prostatectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1984 |
Radical economic surgery and antiandrogenic therapy in management of prostatic cancer.
Topics: Aged; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1980 |
Urinary oxalate excretion during anti-androgenic therapy.
Topics: Aged; Castration; Cyproterone; Cyproterone Acetate; Estradiol; Ethinyl Estradiol; Humans; Male; Middle Aged; Organophosphorus Compounds; Oxalates; Prostatic Neoplasms; Testosterone | 1980 |
[Bioavailability of cyproterone acetate after oral and intramuscular application in men (author's transl)].
Topics: Administration, Oral; Aged; Biological Availability; Cyproterone; Cyproterone Acetate; Humans; Injections, Intramuscular; Male; Middle Aged; Prostatic Neoplasms; Radioimmunoassay | 1980 |
Effects of oestrogens, orchidectomy and cyproterone acetate on salt and water metabolism in carcinoma of the prostate.
Topics: Aged; Castration; Cyproterone; Cyproterone Acetate; Estrogens; Humans; Male; Middle Aged; Plasma Volume; Prostatic Neoplasms; Water-Electrolyte Balance | 1981 |
The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate.
Topics: Aged; Antithrombin III; Castration; Cyproterone; Cyproterone Acetate; Estrogens; Humans; Male; Middle Aged; Prostatic Neoplasms; Thromboembolism | 1981 |
[Effects of cyproterone acetate on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].
Topics: Aged; Antithrombin III; Cardiovascular Diseases; Cyproterone; Cyproterone Acetate; Hemodynamics; Humans; Lipoproteins; Male; Middle Aged; Prostatic Neoplasms; Risk; Water-Electrolyte Balance | 1981 |
Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer.
Topics: Cyproterone; Cyproterone Acetate; Follicle Stimulating Hormone; Humans; Injections, Intramuscular; Kinetics; Luteinizing Hormone; Male; Prolactin; Prostatic Neoplasms; Testosterone | 1981 |
Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer.
Topics: Aged; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Pituitary Gland; Prolactin; Prostatic Neoplasms; Time Factors | 1981 |
Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
Topics: Aged; Castration; Cholesterol Esters; Contraceptive Agents, Male; Cyproterone; Cyproterone Acetate; Estradiol; Estradiol Congeners; Ethinyl Estradiol; Humans; Lipoproteins; Male; Middle Aged; Organophosphorus Compounds; Phosphatidylcholine-Sterol O-Acyltransferase; Prostatic Neoplasms | 1981 |
Neoadjuvant GnRH-agonist treatment (triptorelin and cyproterone acetate for flare protection) and total prostatectomy.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Cyproterone Acetate; Drug Therapy, Combination; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1993 |
Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Cyproterone Acetate; Diethylstilbestrol; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Isoenzymes; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Staging; Orchiectomy; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Time Factors | 1994 |
Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality.
Topics: Aged; Cyproterone Acetate; Goserelin; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 1995 |
Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Topics: Aged; Biopsy; Cyproterone Acetate; Hospitalization; Humans; Male; Middle Aged; Morbidity; Palliative Care; Patient Acceptance of Health Care; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Sweden; Treatment Outcome; Triptorelin Pamoate; Ultrasonography, Interventional | 1994 |
Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma.
Topics: Adenoma; Aged; Contrast Media; Cyproterone Acetate; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Organometallic Compounds; Pentetic Acid; Pituitary Apoplexy; Pituitary Neoplasms; Prostatic Neoplasms; Triptorelin Pamoate | 1995 |
Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.
Topics: Adenocarcinoma; Aged; Animals; Apoptosis; Cyproterone Acetate; Diethylstilbestrol; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Mammary Neoplasms, Experimental; Mice; Middle Aged; Neoplasm Staging; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 1993 |
The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer.
Topics: Cyproterone Acetate; Cystostomy; Goserelin; Humans; Kidney Failure, Chronic; Length of Stay; Male; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Stents; Ureteral Obstruction; Ureterostomy | 1994 |
Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro.
Topics: Androgen Antagonists; Cell Division; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Finasteride; Flutamide; Humans; Linear Models; Male; Prostatic Neoplasms; Testosterone; Tumor Cells, Cultured | 1995 |
[Clinical studies in prostatic carcinoma].
Topics: Aged; Aged, 80 and over; Carcinoma; Combined Modality Therapy; Cyproterone Acetate; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prostatectomy; Prostatic Neoplasms; Remission Induction | 1993 |
Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Topics: Amino Acid Sequence; Androgen Antagonists; Binding, Competitive; Blotting, Western; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Gene Expression Regulation, Viral; Humans; Imidazoles; Imidazolidines; Male; Mammary Tumor Virus, Mouse; Molecular Sequence Data; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1994 |
Fatal fulminant hepatitis from cyproterone acetate.
Topics: Aged; Aged, 80 and over; Cyproterone Acetate; Fatal Outcome; Hepatic Encephalopathy; Humans; Male; Prostatic Neoplasms | 1994 |
Androcur 50 in the treatment of prostatic carcinoma. Belgian multicentric study with the participation of 30 urologists.
Topics: Aged; Cyproterone Acetate; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms; Quality of Life | 1994 |
Cyproterone acetate: hepatotoxicity and prostatic cancer treatment.
Topics: Aged; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Humans; Liver; Male; Prostatic Neoplasms | 1993 |
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Western; Cell Line; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dose-Response Relationship, Drug; Flutamide; Humans; Male; Metribolone; Mutagenesis, Site-Directed; Nitriles; Point Mutation; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Threonine; Tosyl Compounds; Transcription, Genetic; Transfection; Transformation, Genetic; Tumor Cells, Cultured | 1993 |
Advanced prostate cancer. The role of high priced hormone therapy.
Topics: Combined Modality Therapy; Cyproterone Acetate; Diagnosis-Related Groups; Drug Costs; Drug Therapy, Combination; Flutamide; Goserelin; Health Care Costs; Humans; Male; Orchiectomy; Prostatic Neoplasms; Queensland | 1993 |
Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues.
Topics: Cholesterol; Cyproterone Acetate; Drug Therapy, Combination; Goserelin; Humans; Lipoproteins; Male; Prostatic Neoplasms; Triglycerides | 1993 |
Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma.
Topics: Adenocarcinoma; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Cyproterone Acetate; Humans; Male; Methylprednisolone; Middle Aged; Orchiectomy; Prostatic Neoplasms; Scleroderma, Systemic | 1993 |
Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma.
Topics: Androgen Antagonists; Animals; Cyproterone Acetate; Flutamide; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate; Prostatic Neoplasms; Rats; Tenascin; Tumor Cells, Cultured | 1996 |
DNA ploidy patterns in androgen-deprived localized prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cyproterone Acetate; DNA, Neoplasm; Flow Cytometry; Humans; Male; Middle Aged; Ploidies; Prostatectomy; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate | 1996 |
Severe hepatitis and liver failure induced by cyproterone acetate.
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Humans; Liver Cirrhosis; Liver Failure; Liver Function Tests; Male; Prostatic Neoplasms | 1996 |
[The treatment of prostatic carcinoma with cyproterone acetate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cyproterone Acetate; Drug Evaluation; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1996 |
Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; alpha-Fetoproteins; Androgen Antagonists; Antineoplastic Agents; Cyproterone Acetate; Follow-Up Studies; gamma-Glutamyltransferase; Humans; L-Lactate Dehydrogenase; Liver; Liver Neoplasms; Male; Middle Aged; Organ Size; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Transaminases; Treatment Outcome | 1996 |
Re: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer.
Topics: Androgen Antagonists; Cyproterone Acetate; Humans; Male; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1997 |
Cyproterone acetate monotherapy in advanced prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Carcinoma; Cyproterone Acetate; Disease Progression; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Testosterone; Treatment Outcome | 1997 |
Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Carcinosarcoma; Cyproterone Acetate; Humans; Immunohistochemistry; Male; Neoplasms, Multiple Primary; Prostatectomy; Prostatic Neoplasms; Receptors, Progesterone | 1997 |
A pilot study of intermittent androgen deprivation in advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Feasibility Studies; Follow-Up Studies; Humans; Leuprolide; Male; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms | 1998 |
[Therapy of vasomotor syndrome in the treatment of advanced prostatic cancer: apropos of 37 cases].
Topics: Aged; Androgen Antagonists; Castration; Cyproterone Acetate; Hot Flashes; Humans; Male; Middle Aged; Prostatic Neoplasms | 1998 |
[Drug treatment of prostatic carcinoma].
Topics: Androgen Antagonists; Antineoplastic Agents; Cyproterone Acetate; Humans; Libido; Male; Prostatic Neoplasms | 1997 |
[Acute hepatic necrosis in a patient treated with cyproterone acetate].
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Cholangiopancreatography, Endoscopic Retrograde; Cyproterone Acetate; Humans; Liver; Liver Function Tests; Male; Necrosis; Prostatic Neoplasms; Time Factors | 1998 |
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cyproterone Acetate; Drug Interactions; Flutamide; Humans; Imidazoles; Male; Mifepristone; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Binding; Protein Conformation; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 1998 |
Control of the proliferation of prostate cancer cells by an androgen and two antiandrogens. Cell specific sets of responses.
Topics: Androgen Antagonists; Cell Division; Cyproterone Acetate; Genes, myc; Humans; Imidazoles; Kinetics; Male; Metribolone; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; RNA, Messenger; Testosterone Congeners; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
[Treatment of metastatic prostate cancer: certainty and doubts].
Topics: Androgen Antagonists; Antineoplastic Agents; Cyproterone Acetate; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms | 1998 |
Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid.
Topics: Alitretinoin; Animals; Anticarcinogenic Agents; Carcinogens; Cyproterone Acetate; Dose-Response Relationship, Drug; Male; Methylnitrosourea; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Rats; Rats, Wistar; Testosterone; Tretinoin | 1999 |
Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Drug Implants; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 1999 |
Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone.
Topics: Adenocarcinoma; Administration, Oral; Animals; Anticarcinogenic Agents; Carcinoma; Cyproterone Acetate; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Male; Methylnitrosourea; Prostatic Neoplasms; Rats; Rats, Wistar; Testosterone; Time Factors | 1999 |
Antiandrogen hepatotoxicity in patients with chronic viral hepatitis.
Topics: Aged; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Flutamide; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Liver Diseases; Liver Function Tests; Male; Prostatic Neoplasms; Retrospective Studies | 1999 |
Fatigue in patients with prostate cancer receiving hormone therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyproterone Acetate; Fatigue; Female; Goserelin; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Regression Analysis; Severity of Illness Index; Surveys and Questionnaires | 2000 |
Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Humans; Leuprolide; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Prostatectomy; Prostatic Neoplasms; Recurrence; Treatment Outcome | 2000 |
Rapid androgen actions on calcium signaling in rat sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 picomolar and 100 nanomolar concentrations.
Topics: Androgen Antagonists; Androgens; Animals; Calcium Signaling; Cell Line; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Gap Junctions; Humans; Kinetics; Male; Metribolone; Prostate; Prostatic Neoplasms; Rats; Rats, Wistar; Sertoli Cells; Testosterone; Tumor Cells, Cultured | 2000 |
'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Hot Flashes; Humans; Male; Middle Aged; Orchiectomy; Prostatectomy; Prostatic Neoplasms | 2000 |
Androgen blockade in prostate cancer.
Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta-Analysis as Topic; Orchiectomy; Prostatic Neoplasms | 2000 |
Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Capillary Permeability; Cyproterone Acetate; Drug Therapy, Combination; Goserelin; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms | 2001 |
Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyproterone Acetate; Humans; Lymph Nodes; Male; Middle Aged; Postoperative Care; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Outcome; Triptorelin Pamoate | 2000 |
Endothelin-1 in human prostatic carcinoma treated with androgen withdrawal: an immunohistochemical study.
Topics: Aged; Antineoplastic Agents, Hormonal; Cyproterone Acetate; Endothelin-1; Goserelin; Humans; Immunoenzyme Techniques; Leuprolide; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms; Receptors, Androgen; Treatment Outcome | 2001 |
Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cyproterone Acetate; Diagnosis, Differential; Femur Head Necrosis; Humans; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy | 2001 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2001 |
Acute hepatitis induced by cyproterone acetate.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 2001 |
[Brain metastasis of prostatic cancer: regression under hormonal treatment].
Topics: Adenocarcinoma; Adult; Androgen Antagonists; Brain Neoplasms; Cyproterone Acetate; Fatal Outcome; Humans; Male; Prostatic Neoplasms; Remission Induction | 2001 |
NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormone regulatory effects in vivo.
Topics: Acid Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Cyproterone Acetate; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Diethylstilbestrol; Estradiol; Estramustine; Flutamide; Hormones; Humans; Hydrocortisone; Killer Cells, Natural; Male; Orchiectomy; Prolactin; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunoassay; Testosterone | 1992 |
Regression of lymphadenopathy in patient with prostatic carcinoma after hormonal manipulation.
Topics: Aged; Cyproterone Acetate; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Prostatic Neoplasms; Retroperitoneal Space | 1992 |
Endocrine treatment prior to radical retropubic prostatectomy in patients with T3 prostate cancer: a retrospective study of 22 patients.
Topics: Aged; Biopsy; Carcinoma; Combined Modality Therapy; Cyproterone Acetate; Humans; Male; Neoplasm Recurrence, Local; Prostate; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Time Factors; Triptorelin Pamoate | 1992 |
Fifteen years' experience of combined hormone/chemotherapy in metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Retrospective Studies | 1992 |
Induction of proliferative lesions of ventral prostate, seminal vesicle, and other accessory sex glands in rats by N-methyl-N-nitrosourea: effect of castration, pretreatment with cyproterone acetate and testosterone propionate and rat strain.
Topics: Androgens; Animals; Cyproterone; Cyproterone Acetate; DNA Replication; DNA, Neoplasm; Genital Neoplasms, Male; Male; Methylnitrosourea; Orchiectomy; Prostatic Neoplasms; Rats; Rats, Inbred F344; Rats, Inbred Strains; Seminal Vesicles; Testis; Testosterone; Time Factors | 1992 |
[A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
Topics: Aged; Androgen Antagonists; Angina Pectoris; Buserelin; Calcitonin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Hyperhidrosis; Male; Prostatic Neoplasms | 1992 |
[Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Neoplasm; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Testosterone | 1990 |
Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
Topics: Acid Phosphatase; Antigens, Neoplasm; Antineoplastic Agents; APUD Cells; Biomarkers, Tumor; Carcinoembryonic Antigen; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Flutamide; Humans; Male; Orchiectomy; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms | 1991 |
Severe hepatocellular dysfunction following cyproterone acetate therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 1991 |
[Stenosis of the rectum. A rare complication of prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Barium Sulfate; Cyproterone; Cyproterone Acetate; Enema; Humans; Male; Prostatic Neoplasms; Radiography; Rectal Diseases; Rectum | 1991 |
Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Buserelin; Cyproterone; Cyproterone Acetate; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Radioimmunoassay; Receptors, Gonadotropin; Testis; Testosterone | 1991 |
[Fatal subfulminant hepatitis caused by cyproterone acetate].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 1991 |
Hepatocellular carcinoma and treatment with cyproterone acetate.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyproterone; Cyproterone Acetate; Humans; Liver Neoplasms; Male; Prostatic Neoplasms | 1991 |
Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2'-dimethyl-4-aminobiphenyl after sequential treatment
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Aminobiphenyl Compounds; Animals; Body Weight; Cyproterone; Cyproterone Acetate; Genitalia, Male; Male; Methylnitrosourea; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Sarcoma, Experimental; Survival Analysis; Testosterone | 1990 |
Lobar collapse due to endobronchial metastatic prostatic carcinoma: re-expansion with antiandrogen treatment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Humans; Lung; Lung Neoplasms; Male; Prostatic Neoplasms; Pulmonary Atelectasis | 1990 |
Severe hepatitis caused by cyproterone acetate.
Topics: Adenocarcinoma; Aged; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liver Injury; Cyproterone; Cyproterone Acetate; Humans; Liver; Male; Prostatic Neoplasms | 1990 |
[Transrectal echography and cancer of the prostate. III. Monitoring of the treatment response].
Topics: Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Humans; Male; Prostatic Neoplasms; Ultrasonography | 1990 |
Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Luteinizing Hormone; Male; Premedication; Prostatic Neoplasms; Testosterone; Time Factors | 1990 |
[Hepatitis after treatment with cyproterone acetate. Apropos of a case].
Topics: Adenocarcinoma; Aged; Chemical and Drug Induced Liver Injury; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms | 1990 |
Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Fluorouracil; Humans; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1990 |
Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion.
Topics: Acid Phosphatase; Androgen Antagonists; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; ErbB Receptors; Estradiol; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Tumor Cells, Cultured | 1990 |
The synthetic androgen mibolerone induces transient suppression of the transformed phenotype in an androgen responsive human prostatic carcinoma cell line.
Topics: Androgen Antagonists; Androgens; Cell Division; Cell Transformation, Neoplastic; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Humans; Male; Nandrolone; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tumor Cells, Cultured | 1990 |
Effect of oestrogen or cyproterone acetate treatment on adrenocortical function in prostate carcinoma patients.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aged; Circadian Rhythm; Cyproterone; Cyproterone Acetate; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Estradiol; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal Function Tests; Pituitary-Adrenal System; Prolactin; Prostatic Hyperplasia; Prostatic Neoplasms; Testosterone | 1986 |
Management of metastatic prostatic carcinoma.
Topics: Adrenalectomy; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Gonadotropin-Releasing Hormone; Humans; Hypophysectomy; Ketoconazole; Male; Orchiectomy; Palliative Care; Prostatic Neoplasms | 1986 |
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
Topics: Adrenal Glands; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Organ Size; Ornithine Decarboxylase; Progesterone Congeners; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Spironolactone | 1987 |
Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice.
Topics: Androgens; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Female; Flutamide; Male; Mammary Neoplasms, Experimental; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Mice; Progesterone Congeners; Prostatic Neoplasms | 1988 |
[Cyproterone acetate in the treatment of post-orchiectomy flushing].
Topics: Aged; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flushing; Humans; Male; Middle Aged; Orchiectomy; Postoperative Complications; Prostatic Neoplasms | 1989 |
[Treatment of cancer of the prostate. New hormonal approaches].
Topics: Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prostatic Neoplasms; Testosterone | 1989 |
Breathlessness in patients with prostatic carcinoma treated with cyproterone acetate.
Topics: Aged; Cyproterone; Cyproterone Acetate; Dyspnea; Humans; Male; Prostatic Neoplasms | 1989 |
Re: The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Topics: Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Drug Therapy, Combination; Humans; Male; Prostatic Neoplasms | 1989 |
Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Humans; Leydig Cells; Male; Middle Aged; Prostatic Neoplasms; Sertoli Cells; Spermatogenesis; Testicular Diseases; Testosterone | 1989 |
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Rats; Tosyl Compounds | 1989 |
[Chronic myeloid leukemia and carcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Busulfan; Cyproterone; Cyproterone Acetate; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Multiple Primary; Prostatic Neoplasms; Remission Induction | 1989 |
[Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Flutamide; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1989 |
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Goserelin; Imidazoles; Imidazolidines; Ketoconazole; Luteinizing Hormone; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains | 1988 |
[Chemotherapy of advanced prostate cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cyproterone; Cyproterone Acetate; Fluorouracil; Humans; Male; Methotrexate; Neoplasm Staging; Orchiectomy; Prognosis; Prostatic Neoplasms | 1986 |
Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.
Topics: Buserelin; Cyproterone; Cyproterone Acetate; Goserelin; Humans; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Prostatic Neoplasms; Urologic Diseases | 1986 |
Age dependency of androgen and estrogen effects on incorporation of (3H)-thymidine by rat prostates in organ culture.
Topics: Adenocarcinoma; Age Factors; Androgens; Animals; Cyproterone; Cyproterone Acetate; Estradiol; Estrogens; Insulin; Male; Mice; Organ Culture Techniques; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Testosterone | 1986 |
Treatment of prostatic cancer. Newer forms of androgen deprivation.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Megestrol; Megestrol Acetate; Neoplasm Metastasis; Orchiectomy; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1986 |
Hormonal therapy of advanced prostatic cancer.
Topics: Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Prostatic Neoplasms | 1986 |
Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
Topics: Androgens; Cell Division; Cell Line; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Estrenes; Humans; Male; Metribolone; Neoplasm Proteins; Prostate; Prostatic Neoplasms; Receptors, Androgen; Triamcinolone Acetonide | 1986 |
Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity.
Topics: Animals; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Estrogens; Genitalia, Male; Male; Mice; Organ Size; Progesterone; Prostatic Neoplasms; Rats; Stilbenes; Tamoxifen; Testosterone | 1986 |
Therapeutic approaches in prostatic cancer.
Topics: Aged; Aneuploidy; Cyproterone; Cyproterone Acetate; Diploidy; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prostatic Neoplasms; Receptors, Androgen | 1986 |
Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Topics: Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Humans; Male; Premedication; Prostatic Neoplasms; Testosterone | 1986 |
Characterization of androgen receptors in a transplantable human prostatic adenocarcinoma (PC-82).
Topics: Adenocarcinoma; Cell Line; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Estradiol; Estrenes; Humans; Male; Metribolone; Molecular Weight; Neoplasm Transplantation; Progesterone; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Triamcinolone Acetonide | 1987 |
Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy.
Topics: Aged; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Time Factors | 1987 |
Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
Topics: Buserelin; Cyproterone; Cyproterone Acetate; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Prospective Studies; Prostatic Neoplasms; Testosterone; Time Factors | 1987 |
Decrease of serum testosterone by cyproterone acetate accompanied by an unexpected increase of calcitonin secretion capacity.
Topics: Aged; Aged, 80 and over; Calcitonin; Cyproterone; Cyproterone Acetate; Humans; Male; Prostatic Neoplasms; Testosterone | 1987 |
Treatment of advanced carcinoma of the prostate by LHRH-agonists.
Topics: Buserelin; Cyproterone; Cyproterone Acetate; Goserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1987 |
The kinetics of antiandrogens in humans.
Topics: Androgen Antagonists; Anilides; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1987 |
Treatment of prostatic cancer with cyproterone acetate as monotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Prostatic Neoplasms | 1987 |
[Therapy of prostatic cancer with cyproterone acetate].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prostatectomy; Prostatic Neoplasms | 1988 |
Effect of stilboestrol and testosterone on the incorporation of 75selenomethionine by prostatic carcinoma cells.
Topics: Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estradiol; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; Selenomethionine; Testosterone; Tumor Cells, Cultured | 1988 |
[Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Humans; Male; Neoplasm Staging; Prostatic Neoplasms | 1988 |
[Cyproterone acetate. Its value in the treatment of prostatic cancer. Apropos of 45 cases].
Topics: Acid Phosphatase; Androgen Antagonists; Bone Neoplasms; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Radionuclide Imaging; Retrospective Studies | 1988 |
The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Drug Evaluation; Drug Synergism; Gonadotropins, Pituitary; Humans; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Testosterone | 1988 |
Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Topics: Aged; Aged, 80 and over; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1988 |
Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study.
Topics: Androgen Antagonists; Carcinoma; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Europe; Gonadotropin-Releasing Hormone; Hormones; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms | 1988 |
Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment.
Topics: Adenocarcinoma; Aged; Castration; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Estradiol; Estradiol Congeners; Estrogens; Ethinyl Estradiol; Humans; Male; Middle Aged; Prostatic Neoplasms; Urethral Obstruction | 1985 |
[Therapy of virginal prostatic cancer with cyproterone acetate].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Humans; Male; Middle Aged; Neoplasm Staging; Prostate; Prostatic Neoplasms; Testosterone | 1985 |